NCT00551070 · OUTCOME

Area Under the Curve (AUC) for AZD6244, 100 mg Administered Orally Twice Daily.

Selumetinib Sulfate in Treating Woman With Recurrent Low-Grade Ovarian Cancer or Peritoneum Cancer · Source last updated 2020-12-03

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: MEDIAN
Unit: ng x hr/mL
Interval / dispersion: Inter-Quartile Range
Time frame: Pre-dose, and 1, 3, and 6 hours after administration of drug on Day 7 after the start of AZD6244 treatment

Analysis population: Eligible and Treated Patients with all pharmacokinetic time points available

Groups in this outcome

AZD6244 (NSC #748727) 100 mg orally BID until disease progression or adverse effects prohibit further therapy (1 cycle =28 days)

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
AZD6244	41

Source class 1

Values in ng x hr/mL · Interval/dispersion: Inter-Quartile Range
Group	Value	Spread	Lower	Upper	Comment
AZD6244	2419	Not reported	1673	3186	Not reported

Complete source fields

classes

denoms

dispersion Type

Inter-Quartile Range

groups

param Type

MEDIAN

population Description

Eligible and Treated Patients with all pharmacokinetic time points available

reporting Status

POSTED

time Frame

Pre-dose, and 1, 3, and 6 hours after administration of drug on Day 7 after the start of AZD6244 treatment

title

Area Under the Curve (AUC) for AZD6244, 100 mg Administered Orally Twice Daily.

type

PRIMARY

unit Of Measure

ng x hr/mL

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice